DEFR14A: IN8bio Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

IN8bio is asking stockholders to approve a reverse stock split to maintain its listing on the Nasdaq Capital Market and potentially improve stock marketability.

Summary

• IN8bio, Inc. is holding its 2025 Annual Meeting of Stockholders virtually on May 8, 2025.
• The meeting will address the election of three Class I directors, ratification of CohnReznick LLP as the independent accounting firm, and approval of a reverse stock split.
• The proposed reverse stock split would be at a ratio between 1-for-15 and 1-for-30, determined by the board.
• The board believes a reverse stock split is necessary to maintain its Nasdaq listing and improve stock marketability.
• If the reverse stock split is approved, the board has the discretion to implement it before May 8, 2026.
• The company is seeking approval to amend its certificate of incorporation to allow for the reverse stock split.
• The company's stock price closed below $1.00 per share for 30 consecutive business days, triggering a Nasdaq notification.
• The company has until August 4, 2025, to regain compliance with the minimum bid price requirement.
• The company expects to pay Morrow Sodali LLC a fee of $20,000 plus reasonable expenses for proxy solicitation services.
• As of the record date, March 12, 2025, there were 81,258,763 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focusing on procedural matters and compliance requirements. The need for a reverse stock split suggests underlying financial challenges, but the document aims to present it as a strategic move for long-term stability.

Positives

• Maintaining the Nasdaq listing could improve market liquidity and investor confidence.
• A higher stock price post-split could attract institutional investors and analysts.
• The board has the flexibility to choose the reverse stock split ratio within a specified range.
• The company has engaged Morrow Sodali LLC to solicit proxies.

Negatives

• The reverse stock split could decrease the liquidity of the common stock.
• The reverse stock split may increase transaction costs for stockholders owning odd lots.
• The company cannot guarantee that the reverse stock split will increase the stock price or maintain Nasdaq compliance.
• The effective increase in authorized shares could have anti-takeover implications.

Risks

• The company may not regain compliance with the Nasdaq minimum bid price requirement.
• Delisting from Nasdaq could negatively impact the company's ability to raise capital and its reputation.
• The market price of the common stock may decrease even after the reverse stock split.
• The reverse stock split may not achieve the desired results of increasing marketability and liquidity of the common stock.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements and improve its stock's marketability through the proposed reverse stock split.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. The success of such splits varies depending on the company's underlying fundamentals and market conditions.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges have implemented reverse stock splits to maintain exchange listings.
• Comparable companies that have recently undertaken reverse stock splits include Allarity Therapeutics, Inc. and IMV, Inc.
• The effectiveness of a reverse stock split depends on the company's ability to improve its financial performance and investor sentiment following the split.

Management Changes

Related Party Transactions

• Certain directors, officers, and major stockholders participated in the 2024 and 2023 private placements.
• The company amended certain Series A Warrants held by directors, officers, and major stockholders in connection with the 2024 Private Placement.
• Mr. Ho agreed to a further reduction in his annual base salary in connection with the closing of the 2024 Private Placement.

Stakeholder Impact

• Stockholders may experience a change in the number of shares they own if the reverse stock split is implemented.
• The company's ability to attract and retain employees could be affected by the stock price and Nasdaq listing status.
• The company's access to capital markets could be impacted by its Nasdaq listing status.

Next Steps

• Stockholder vote on the proposals at the Annual Meeting on May 8, 2025.
• Board decision on whether to implement the reverse stock split and at what ratio, if approved.
• Filing of the Certificate of Amendment with the Secretary of State of Delaware if the reverse stock split is implemented.
• Continued efforts to meet Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, Nasdaq, proxy statement, minimum bid price, stockholders, directors, CohnReznick, listing, compliance, IN8bio